EpimAb Biotherapeutics Inc.’s HKEX IPO Application Lapsed, Dual Antibody Pipeline Centered on EGFR/cMET

NewTimeSpace · 2026/06/18 09:49 · By Zehong Cheng

NewTimeSpace News: The listing application submitted by EpimAb Biotherapeutics Inc. to the Hong Kong Stock Exchange on 18 December 2025 has lapsed upon the expiry of the six-month validity period, with CITIC Securities and CMB International Capital serving as the original joint sponsors. Founded in 2015, the Company is a clinical-stage biotech enterprise focusing on the development of bispecific antibodies for various cancers and autoimmune diseases. Its core asset EMB-01 (targeting EGFR/cMET) is mainly indicated for metastatic colorectal cancer, currently under Phase II monotherapy development and Phase Ib combination therapy development.

NewTimeSpace News: The Main Board listing application filed by EpimAb Biotherapeutics Inc. with the Stock Exchange of Hong Kong Limited on 18 December 2025 has lapsed after the six-month statutory validity period expired, with CITIC Securities and China Merchants Bank International acting as the original joint sponsors.

Founded in 2015, the Company is a clinical-stage biotechnology firm dedicated to developing bispecific antibodies for the treatment of diverse cancers and autoimmune disorders. Its self-developed pipeline comprises three clinical-stage drug candidates:Core product EMB-01 (EGFR/cMET bispecific antibody): Primarily indicated for metastatic colorectal cancer, now in Phase II clinical development as third-line monotherapy and Phase Ib clinical development for combination regimens;Two other clinical-stage candidates: EMB-06 (BCMA/CD3) for relapsed/refractory multiple myeloma and autoimmune diseases, EMB-07 (ROR1/CD3) for lymphoma and solid tumors;Four preclinical drug candidates.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

EpimAb Bio IPO IPO application lapsed